DK39892D0 - Peptid - Google Patents

Peptid

Info

Publication number: DK39892D0
Authority: DK; Denmark
Prior art keywords: glp; pct; agonists; receptor; sec
Prior art date: 1992-03-25

Application number

DK92398A

Other languages

Danish (da)

English (en)

Inventor

Bernard Thorens

Original Assignee

Bernard Thorens

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-25

Filing date

1992-03-25

Publication date

1992-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK39892(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-25 Application filed by Bernard Thorens filed Critical Bernard Thorens

1992-03-25 Priority to DK92398A priority Critical patent/DK39892D0/da

1992-03-25 Publication of DK39892D0 publication Critical patent/DK39892D0/da

1993-03-23 Priority to DE69326405T priority patent/DE69326405T2/de

1993-03-23 Priority to DE0586657T priority patent/DE586657T1/de

1993-03-23 Priority to ES93906589T priority patent/ES2070801T1/es

1993-03-23 Priority to PCT/EP1993/000697 priority patent/WO1993019175A1/en

1993-03-23 Priority to AT93906589T priority patent/ATE184648T1/de

1993-03-23 Priority to US08/142,439 priority patent/US5670360A/en

1993-03-23 Priority to AU37512/93A priority patent/AU3751293A/en

1993-03-23 Priority to JP51628793A priority patent/JP3371379B2/ja

1993-03-23 Priority to EP93906589A priority patent/EP0586657B1/de

1995-06-30 Priority to GR950300031T priority patent/GR950300031T1/el

1997-06-05 Priority to US08/869,477 priority patent/US5846747A/en

1997-09-22 Priority to US08/935,317 priority patent/US6051689A/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title 1
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
102100040918 Pro-glucagon Human genes 0.000 abstract 2
239000000556 agonist Substances 0.000 abstract 2
238000012216 screening Methods 0.000 abstract 2
108020004414 DNA Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DK92398A 1992-03-25 1992-03-25 Peptid DK39892D0 (da)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
DK92398A DK39892D0 (da)	1992-03-25	1992-03-25	Peptid
EP93906589A EP0586657B1 (de)	1992-03-25	1993-03-23	Receptor für das Glucagon ähnliches Peptid-1 (GLP-1)
JP51628793A JP3371379B2 (ja)	1992-03-25	1993-03-23	グルカゴン様ペプチド−１（ｇｌｐ−１）に対するレセプター
AT93906589T ATE184648T1 (de)	1992-03-25	1993-03-23	Receptor für das glucagon ähnliches peptid-1 (glp-1)
DE0586657T DE586657T1 (de)	1992-03-25	1993-03-23	Receptor für das Glucagon ähnliches Peptid-1 (GLP-1).
ES93906589T ES2070801T1 (es)	1992-03-25	1993-03-23	Receptor para el peptido-1 similar al glucagon (glp-1).
PCT/EP1993/000697 WO1993019175A1 (en)	1992-03-25	1993-03-23	Receptor for the glucagon-like-peptide-1 (glp-1)
DE69326405T DE69326405T2 (de)	1992-03-25	1993-03-23	Receptor für das Glucagon ähnliches Peptid-1 (GLP-1)
US08/142,439 US5670360A (en)	1992-03-25	1993-03-23	Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresponding DNA and recombinant expression systems, and screening assays for GLP-1 agonists and enhancers
AU37512/93A AU3751293A (en)	1992-03-25	1993-03-23	Receptor for the glucagon-like-peptide-1 (GLP-1)
GR950300031T GR950300031T1 (en)	1992-03-25	1995-06-30	Receptor for the glucagon-like-peptide-1 (glp-1).
US08/869,477 US5846747A (en)	1992-03-25	1997-06-05	Method for detecting glucagon-like peptide-1 antagonists and agonists
US08/935,317 US6051689A (en)	1992-03-25	1997-09-22	Receptor for the glucagon-like-peptide (GLP-1)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK92398A DK39892D0 (da)	1992-03-25	1992-03-25	Peptid

Publications (1)

Publication Number	Publication Date
DK39892D0 true DK39892D0 (da)	1992-03-25

Family

ID=8093079

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92398A DK39892D0 (da)	1992-03-25	1992-03-25	Peptid

Country Status (10)

Country	Link
US (2)	US5670360A (de)
EP (1)	EP0586657B1 (de)
JP (1)	JP3371379B2 (de)
AT (1)	ATE184648T1 (de)
AU (1)	AU3751293A (de)
DE (2)	DE586657T1 (de)
DK (1)	DK39892D0 (de)
ES (1)	ES2070801T1 (de)
GR (1)	GR950300031T1 (de)
WO (1)	WO1993019175A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6849708B1 (en)	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en)	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US5846747A (en) *	1992-03-25	1998-12-08	Novo Nordisk A/S	Method for detecting glucagon-like peptide-1 antagonists and agonists
DK39892D0 (da) *	1992-03-25	1992-03-25	Bernard Thorens	Peptid
EP0969016A2 (de) *	1992-06-15	2000-01-05	Scios Inc.	Dem Glukagon ähnliche Peptide und Insulinotropin-Derivate
HU219674B (hu) *	1992-08-28	2001-06-28	Novo Nordisk A/S	Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1995004821A1 (en) *	1993-08-09	1995-02-16	Merck & Co., Inc.	Human glucagon-like 1 peptide receptor
GB9502830D0 (en) *	1995-02-14	1995-04-05	Ecole Polytech	Regulation of polypeptide production in cells
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DE69737561T2 (de) *	1996-12-13	2008-03-06	Nps Allelix Corp., Toronto	Klonierte rezeptoren des glukagon-ähnlichen peptids-2
US8592553B2 (en)	1996-12-13	2013-11-26	Nps Pharmaceuticals, Inc.	Cloned glucagon-like peptide-2 receptors
ATE251465T1 (de)	1998-07-31	2003-10-15	Novo Nordisk As	In-vitro stimulation von beta zellen vermehrung
JP2002528721A (ja) *	1998-10-23	2002-09-03	グラクソグループリミテッド	核内受容体のリガンド用のアッセイ
ES2253353T3 (es)	2000-03-08	2006-06-01	Novo Nordisk A/S	Reduccion del colesterol serico.
US6448045B1 (en)	2000-03-10	2002-09-10	The Regents Of The University Of California	Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US20020123071A1 (en) *	2000-12-04	2002-09-05	Knudsen Sanne Moller	Method of identifying compounds capable of acting as agonists or antagonists of G-protein coupled receptors
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
US6911324B2 (en) *	2001-10-18	2005-06-28	The Regents Of The University Of California	Induction of beta cell differentiation in human cells
EP1474163A2 (de)	2002-01-10	2004-11-10	Imperial College Innovations Limited	Veränderung des fütterungsverhaltens
US7141240B2 (en) *	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
WO2004005342A1 (en)	2002-07-04	2004-01-15	Zealand Pharma A/S	Glp-1 and methods for treating diabetes
BR0314996A (pt) *	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004071393A2 (en) *	2003-02-13	2004-08-26	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
WO2005018536A2 (en) *	2003-05-23	2005-03-03	Human Genome Sciences, Inc.	Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
DK3300721T4 (da)	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
EP2298337B1 (de)	2003-12-09	2017-02-22	Novo Nordisk A/S	Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
EP1758575A1 (de)	2004-06-11	2007-03-07	Novo Nordisk A/S	Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
WO2006133333A2 (en)	2005-06-07	2006-12-14	The Rockefeller University	Stimulation of pancreatic b cell proliferation
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
US8718994B2 (en) *	2008-04-09	2014-05-06	Transtech Pharma, Llc	Ligands for the GLP-1 receptor and methods for discovery thereof
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
WO2011123943A1 (en)	2010-04-09	2011-10-13	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CN107129538B (zh)	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
SI2651398T1 (en)	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
EP2788027A2 (de)	2011-12-09	2014-10-15	Novo Nordisk A/S	Glp-1-agonisten
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es)	2012-03-22	2024-04-15	Novo Nordisk As	Composiciones que comprenden un agente de suministro y preparación de estas
EP2866825B1 (de)	2012-07-01	2020-04-08	Novo Nordisk A/S	Verwendung von glp-1-peptiden mit langzeitwirkung
IN2015DN00544A (de)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
WO2014060472A1 (en)	2012-10-17	2014-04-24	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
ES2630106T3 (es)	2014-10-07	2017-08-18	Cyprumed Gmbh	Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
JP2018529749A (ja)	2015-10-07	2018-10-11	シプルメット・ゲーエムベーハー	ペプチド薬物を経口送達するための医薬製剤
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EP3551651B1 (de)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylierte glp-1/glp-2 duale agoniste
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
WO2019193204A1 (en)	2018-04-06	2019-10-10	Cyprumed Gmbh	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111423506B (zh) *	2019-11-08	2023-06-27	成都奥达生物科技有限公司	一种glp-1化合物
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
CN115461044B (zh)	2020-04-29	2025-06-10	诺和诺德股份有限公司	包含glp-1激动剂和组氨酸的固体组合物
EP4210680A1 (de)	2020-09-07	2023-07-19	Cyprumed GmbH	Verbesserte pharmazeutische formulierungen von glp-1-rezeptoragonisten
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (de)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitoren der expression und/oder funktion
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity
DK182293B1 (en)	2025-01-16	2026-02-25	Novo Nordisk As	Semaglutide for use in medical therapy including weight management

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK39892D0 (da) *	1992-03-25	1992-03-25	Bernard Thorens	Peptid

1992
- 1992-03-25 DK DK92398A patent/DK39892D0/da not_active Application Discontinuation
1993
- 1993-03-23 EP EP93906589A patent/EP0586657B1/de not_active Expired - Lifetime
- 1993-03-23 AT AT93906589T patent/ATE184648T1/de not_active IP Right Cessation
- 1993-03-23 WO PCT/EP1993/000697 patent/WO1993019175A1/en not_active Ceased
- 1993-03-23 JP JP51628793A patent/JP3371379B2/ja not_active Expired - Lifetime
- 1993-03-23 ES ES93906589T patent/ES2070801T1/es active Pending
- 1993-03-23 AU AU37512/93A patent/AU3751293A/en not_active Abandoned
- 1993-03-23 US US08/142,439 patent/US5670360A/en not_active Expired - Lifetime
- 1993-03-23 DE DE0586657T patent/DE586657T1/de active Pending
- 1993-03-23 DE DE69326405T patent/DE69326405T2/de not_active Expired - Lifetime
1995
- 1995-06-30 GR GR950300031T patent/GR950300031T1/el unknown
1997
- 1997-09-22 US US08/935,317 patent/US6051689A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU3751293A (en)	1993-10-21
US6051689A (en)	2000-04-18
JP3371379B2 (ja)	2003-01-27
ATE184648T1 (de)	1999-10-15
EP0586657B1 (de)	1999-09-15
US5670360A (en)	1997-09-23
DE69326405T2 (de)	2000-03-23
WO1993019175A1 (en)	1993-09-30
GR950300031T1 (en)	1995-06-30
DE586657T1 (de)	1996-01-18
EP0586657A1 (de)	1994-03-16
ES2070801T1 (es)	1995-06-16
JPH06508765A (ja)	1994-10-06
DE69326405D1 (de)	1999-10-21

Legal Events

Date	Code	Title	Description
1992-10-26	AHS	Application shelved for other reasons than non-payment

Publication	Publication Date	Title
DK39892D0 (da)	1992-03-25	Peptid
DK1482042T3 (da)	2009-06-15	Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DK0758383T3 (da)	2007-05-29	Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
ATE193541T1 (de)	2000-06-15	Insulinotropes hormon
IL112112A (en)	2000-06-29	Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
DK0667910T3 (da)	2003-12-01	En Bacillus-promoter, afledt fra en variant af en alpha-amylase-promoter fra Bacillus licheniformis
DK0675956T3 (da)	2003-07-07	Nyt protein fra urin betegnet komponent B
DE69938669D1 (de)	2008-06-19	Analoge des glucagon ähnlichen peptides-1 (glp-1)
DK0591914T3 (da)	1999-08-16	Retrovirus fra HIV-gruppen og dets anvendelse
ATE106943T1 (de)	1994-06-15	Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
AU1208497A (en)	1997-07-28	Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
ATE389416T1 (de)	2008-04-15	Behandlung von knorpelerkrankungen
IE900793L (en)	1990-09-07	Recombinant protein receptor
FI952094A0 (fi)	1995-05-02	Ihmisen serotoniinireseptoria (5-HT4B)koodaava DNA ja sen käyttö
ATE225806T1 (de)	2002-10-15	D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
DK0652964T3 (da)	2006-05-08	Promotor af K. lactis transaldolasegenet og anvendelse heraf
DE59206628D1 (en)	1996-07-25	Expression signalpeptid-freier staphylokinasen
DK0773999T3 (da)	2002-07-22	OR-1, en orphan-receptor tilhørende kernereceptorfamilien
DE69737561D1 (de)	2007-05-16	Klonierte rezeptoren des glukagon-ähnlichen peptids-2
FR2693200B1 (fr)	1994-08-19	Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations.
ES2059801T3 (es)	1994-11-16	Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
MX9606720A (es)	1997-03-29	Polipeptidos con dominios de enlace al receptor 1 de la interleucina 8(il8r1).
DK0487229T3 (da)	1997-12-29	DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
NO940797L (no)	1994-03-07	Reseptorderivater som har bindingseter for human-rhinovirus

DK39892D0 - Peptid - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (13)

Applications Claiming Priority (1)

Publications (1)

Family

ID=8093079

Family Applications (1)

Country Status (10)

Families Citing this family (89)

Family Cites Families (1)

Also Published As

Similar Documents

Legal Events